AxoGen, Inc. (NASDAQ:AXGN) Director Amy Mcbride Wendell Sells 5,000 Shares

AxoGen, Inc. (NASDAQ:AXGN) Director Amy Mcbride Wendell sold 5,000 shares of AxoGen stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $20.02, for a total transaction of $100,100.00. Following the completion of the sale, the director now directly owns 97,899 shares in the company, valued at $1,959,937.98. This trade represents a 4.86 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

AxoGen Trading Down 2.2 %

Shares of AXGN stock opened at $18.21 on Thursday. The company’s fifty day simple moving average is $17.84 and its two-hundred day simple moving average is $15.22. The stock has a market capitalization of $807.50 million, a price-to-earnings ratio of -56.91 and a beta of 1.00. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. AxoGen, Inc. has a 1 year low of $5.55 and a 1 year high of $21.00.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. R Squared Ltd purchased a new position in shares of AxoGen during the 4th quarter valued at $30,000. US Bancorp DE purchased a new position in AxoGen in the fourth quarter worth $30,000. State of Wyoming purchased a new position in AxoGen in the fourth quarter worth $31,000. Quest Partners LLC grew its position in AxoGen by 23,066.7% in the third quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 2,076 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd purchased a new position in AxoGen in the fourth quarter worth $93,000. 80.29% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on AXGN. Canaccord Genuity Group lifted their price target on shares of AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, February 26th. Cantor Fitzgerald reissued an “overweight” rating and set a $24.00 target price on shares of AxoGen in a report on Wednesday. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, AxoGen currently has a consensus rating of “Buy” and a consensus target price of $20.75.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.